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Resistance to insulin, which is associated with diabetes, 
can be markedly reduced by the administration of agonists 
of peroxisome proliferator activated receptor γ (PPARγ) 
[1]; this was the basis for the development of several anti-
diabetic  drugs,  including  troglitazone  (Rezulin),  rosigli-
tazone (Avandia) and pioglitazone (Actos). Activation of a 
related receptor, PPARβ/δ, also elicits biological effects in 
mice leading to improved insulin sensitivity [2]. However, 
an  agonist  for  PPARβ/δ  has  not  yet  made  it  into  the 
clinic.
PPARγ  and  PPARβ/δ  are  transcription  factors  and 
members  of  the  nuclear  receptor  superfamily.  They 
control the expression of genes linked to inflammation, 
cell differentiation and lipid and carbohydrate metabo-
lism, and the expression of each is tissue dependent. The 
molecular  mechanisms  by  which  PPARγ  and  PPARβ/δ 
agonists  regulate  glucose  homeostasis  have  not  been 
conclusively  identified  so  far  but  probably  involve 
multiple  tissue  types,  including  skeletal  muscle  and 
adipose [1].
Interestingly,  although  PPARβ/δ  and  PPARγ  agonists 
both increase insulin sensitivity, their cellular effects are 
different: administration of PPARγ agonists is known to 
be associated with accumulation of lipids in adipocytes, 
and  administration  of  PPARβ/δ  agonists  is  associated 
with oxidation of lipids in skeletal muscle. In the latest 
issue of Genome Biology, Julian Griffin and colleagues [3] 
extend these findings and report the effect of activating 
PPARβ/δ or PPARγ in adipocytes. They demonstrate an 
interesting phenotype that helps explain the molecular 
mechanisms  by  which  these  compounds  modulate 
glucose homeostasis [3].
A unique signature of PPAR activation
Griffin and colleagues [3] examined the adipocytes from 
an obese (ob/ob) mouse model of insulin resistance and 
obesity that had been treated with an agonist of either 
PPARβ/δ or PPARγ (GW0742 or GW7845, respectively). 
The  metabolic  signatures  of  the  adipocytes  differed 
depending on the treatment: decreased concentrations of 
long  chain  fatty  acids  were  found  in  cells  from  mice 
treated  with  the  PPARγ  agonist  (GW0742);  this  effect 
was  not  found  in  PPARβ/δ  agonist  (GW7845)-treated 
mouse  adipocytes.  Complementary  analysis  of  mouse 
serum was consistent with these changes, showing that 
certain  circulating  triacylglycerols  were  increased  by 
treat  ment  with  the  PPARβ/δ  ligand,  whereas  the  same 
species of circulating triacylglycerols were decreased by 
treatment with the PPARγ ligand. Thus, distinctly differ-
ent  metabolic  profiles  from  two  agents  that  improve 
insulin sensitivity were identified.
Comparable changes in fatty acids were also detected 
in 3T3-L1 cell line adipocytes following treatment with 
the  PPARβ/δ  or  PPARγ  agonist.  Further  studies  using 
stable isotopic labeling of glucose and palmitate (a sub-
strate for measuring fatty acid metabolism) and micro-
array  analysis  showed  that  activation  of  PPARβ/δ  also 
caused an increase in fatty acid β-oxidation, the tri  car-
boxylic acid cycle rate and the oxidation of some amino 
acids  in  adipocytes.  This  was  in  contrast  to  increased 
synthesis,  elongation  and  storage  of  lipids  observed  in 
adipocytes  following  ligand  activation  of  PPARγ. 
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Metabolomic analysis will provide the next large 
set of clues to further our understanding of human 
health and disease. A recent study has elucidated 
the significant differences in the metabolomes of 
adipocytes, serum and an adipocyte cell line after 
activation of two nuclear receptors, peroxisome 
proliferator activated receptor β/δ (PPARβ/δ) and 
PPARγ. These findings hold great promise for explaining 
fundamental differences in the mechanisms of PPAR 
agonists and for identifying targets for the treatment of 
diabetes.
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the  metabolomic  profile  in  adipocytes  reveal  that  the 
changes  induced  by  activating  PPARβ/δ  or  PPARγ  are 
unique to each receptor and reflect either causally related 
metabolism  or  an  effect  that  directly  reflects  the 
metabolic  consequences  that  contribute  to  the  mecha-
nisms by which these nuclear receptors modulate tissue 
and serum glucose levels. It is worth noting that PPARγ 
and PPARβ/δ cooperatively function to induce differen-
tiation of adipocytes in vitro, facilitated by PPARγ [4], but 
this new study [3] shows that in differentiated adipocytes, 
activating  PPARβ/δ  causes  distinctly  different  effects 
from those resulting from activating PPARγ. The finding 
that PPAR β/δ and PPARγ work together in one situation, 
but not in another, suggests that they function differently 
in different scenarios.
Does the metabolomic signature have clinical 
potential?
Results  from  the  study  by  Griffin  and  colleagues  [3] 
provide  new  insights  into  the  mechanism  of  action  of 
PPARβ/δ and PPARγ agonists in adipocytes, which are 
likely to be essential for explaining the insulin-sensitizing 
effects of these compounds. However, these results also 
raise many questions. Do the changes in lipid, glucose 
and amino acid metabolites in adipocytes following ligand 
activation of either PPARβ/δ or PPARγ reflect causally 
related  events  that  can  be  targeted  for  improved  anti-
diabetic approaches, or do they merely reflect an effect of 
activating the receptor? In other words, can the cellular 
metabolites  be  manipulated  through  diet  or  pharma-
cology to improve insulin resistance, independent of acti-
vat  ing a PPAR? Further studies are needed to distinguish 
between these possibilities and could be developed using 
the findings from Griffin and colleagues [3].
The final question is whether this new metabolic profile 
can  be  used  to  identify  new  PPAR  agonists  that  have 
greater  potency,  efficacy  and/or  reduced  toxicity  for 
diabetes therapy. If metabolites that are causally related 
to  the  improved  insulin  resistance  are  identified,  this 
could provide clues for this purpose. Given the recently 
identified safety problems associated with administration 
of rosiglitazone and cardiac toxicity [5], these new data 
may be particularly useful. Ultimately, approaches such 
as the one described in Genome Biology [3], coupled with 
similar metabolomic profiling in the clinic, will become 
indispensable for understanding and evaluating the on- 
and off-target effects of drugs and their toxicity and will 
move us closer to the realization of personalized medicine.
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